Drug Trial Radar · NCT05139017
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
290
Planned (sponsor's estimate)
Start
Jan 14, 2022
Primary completion
Sep 24, 2027
Study completion Sep 24, 2027
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Dec 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Confirmation (Part 1) and Efficacy Expansion (Part 2) and will enroll participants who are at least 18 years of age with rrDLBCL. The hypotheses are: ZV in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) is superior to R-GemOx with respect to progression-free survival (PFS) per Lugano response criteria by blinded independent review committee (BICR); and that ZV in combination with bendamustine rituximab (BR) is superior to BR with respect to PFS per Lugano response criteria by BICR. With protocol amendment 4 (effective: 04-April-2024), enrollment in Cohort B (study arms Bendamustine Rituximab \[BR\] and ZV + BR) is discontinued. No efficacy outcome analysis and hypothesis testing will be conducted for Cohort B.
Conditions
- DLBCL
- Diffuse Large B-Cell Lymphoma
Interventions
Zilovertamab vedotinBiological
Intravenous (IV) Infusion 1.5 mg/kg, 1.75 mg/kg, 2.0 mg/kg, 2.25 mg/kg, 2.5 mg/kg
RituximabBiological
IV Infusion 375 mg/m\^2
GemcitabineDrug
IV Infusion 1000 mg/m\^2
OxaliplatinDrug
IV Infusion 100 mg/m\^2
BendamustineDrug
IV Infusion 90 mg/m\^2
Granulocyte Colony-Stimulating Factor (G-CSF)Drug
Prophylactic G-CSF will be administered at each cycle of zilovertamab vedotin as per the institutional guidelines.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants who experienced dose-limiting toxicities (DLTs) in Part 1Time frame: Up to ~6 weeks
- Number of participants who experienced an adverse event (AE)Time frame: Up to ~68 months
- Number of participants who discontinued study treatment due to an AETime frame: Up to ~68 months
- Overall survival (OS)Time frame: Up to ~35 months
- Progression-free survival (PFS)Time frame: Up to ~35 months
Locations
135 sites in 26 countries. Site status is shown where the registry gives one.
Palo Verde Hematology/ Oncology Center, Ltd. ( Site 0175)
Glendale, Arizona · Recruiting
Beverly Hills Cancer Center ( Site 0184)
Beverly Hills, California · Active not recruiting
Bass Medical Group ( Site 0166)
Walnut Creek, California · Recruiting
Innovative Clinical Research Institute ( Site 0122)
Whittier, California · Completed
Boca Raton Regional Hospital- Lynn Cancer Institute ( Site 0163)
Boca Raton, Florida · Recruiting
Clermont Oncology Center ( Site 0174)
Clermont, Florida · Recruiting
BRP-Hialeah Hospital ( Site 0182)
Hialeah, Florida · Recruiting
Illinois Cancer Specialists ( Site 8000)
Niles, Illinois · Recruiting
Saint Elizabeth Medical Center Edgewood ( Site 0165)
Edgewood, Kentucky · Recruiting
University of Kentucky Chandler Medical Center ( Site 0158)
Lexington, Kentucky · Active not recruiting
Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0133)
Louisville, Kentucky · Active not recruiting
University of Maryland ( Site 0123)
Baltimore, Maryland · Active not recruiting
Dana-Farber Cancer Institute-Lymphoma ( Site 0111)
Boston, Massachusetts · Active not recruiting
University of Massachusetts Medical School ( Site 0119)
Worcester, Massachusetts · Active not recruiting
Corewell Health ( Site 0162)
Grand Rapids, Michigan · Recruiting
St. Vincent Frontier Cancer Center-Research ( Site 0108)
Billings, Montana · Completed
Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0188)
Grand Island, Nebraska · Recruiting
Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0177)
Omaha, Nebraska · Recruiting
Comprehensive Cancer Centers of Nevada ( Site 0168)
Las Vegas, Nevada · Recruiting
Atlantic Health System ( Site 0116)
Morristown, New Jersey · Completed
Presbyterian Rust Jorgensen Cancer ( Site 9506)
Rio Rancho, New Mexico · Active not recruiting
New York Medical College ( Site 0113)
Valhalla, New York · Completed
Alliance Cancer Specialists (ACS) ( Site 8001)
Horsham, Pennsylvania · Recruiting
Tennessee Cancer Specialists ( Site 7000)
Knoxville, Tennessee · Recruiting
Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 0156)
Nashville, Tennessee · Completed
Blue Ridge Cancer Care ( Site 0169)
Roanoke, Virginia · Active not recruiting
Instituto Alexander Fleming ( Site 2201)
CABA, Argentina · Active not recruiting
Hospital Italiano de Buenos Aires ( Site 2203)
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Active not recruiting
Instituto de Investigaciones Clínicas Mar del Plata ( Site 2205)
Mar del Plata, Buenos Aires, Argentina · Completed
Hospital Aleman ( Site 2200)
Buenos Aites, Buenos Aires F.D., Argentina · Active not recruiting
Hospital Privado Universitario de Córdoba ( Site 2202)
Córdoba, Córdoba Province, Argentina · Active not recruiting
Townsville University Hospital ( Site 1800)
Townsville, Queensland, Australia · Active not recruiting
Grampians Health ( Site 1802)
Ballarat, Victoria, Australia · Recruiting
Royal Perth Hospital-Haematology ( Site 1801)
Perth, Western Australia, Australia · Recruiting
Hospital Paulistano ( Site 2300)
São Paulo, Brazil · Active not recruiting
Hospital Erasto Gaertner ( Site 2302)
Curitiba, Paraná, Brazil · Recruiting
Liga Norte Riograndense Contra o Câncer ( Site 2305)
Natal, Rio Grande do Norte, Brazil · Recruiting
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200)
Toronto, Ontario, Canada · Completed
Biocenter ( Site 2401)
Concepción, Biobio, Chile · Active not recruiting
IC La Serena Research ( Site 2405)
La Serena, Coquimbo Region, Chile · Active not recruiting
Showing 40 of 135 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.